Metformin and Pioglitazone Effects on Fetuin-A and Osteoprotegrin Concentrations in Type 2 Diabetes Patients
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Oral hypoglycemic agents, along with dietary modification and exercise encompass the mainstay
of treatment in early stages of T2DM. Biguanides and thiazolidinediones are two major groups
of hypoglycemic medications that while function via different pathways, mare both effective
in short- and long-term glucose control. These medications diminish or delay long term micro-
and macrovascular complications associated with T2DM although at different rates. Excessive
insulin resistance accounts for a sustained increase in cardiovascular incidents in T2DM
subjects. Given the shared pathway of insulin resistance/fetuin-A/OPG in atherosclerosis
formation, it is conceivable that insulin sensitizing anti-diabetes medications are able to
modify successive CAD risk via direct and indirect amelioration of insulin
resistance/fetuin-A/OPG. The present study is therefore designed to investigate the effects
of metformin and pioglitazone monotherapy on serum concentrations of fetuin-A and OPG in a
group of Iranian adults with newly diagnosed T2DM.